Literature DB >> 16092088

Grading of neuropathology in multiple system atrophy: proposal for a novel scale.

Kurt A Jellinger1, Klaus Seppi, Gregor K Wenning.   

Abstract

Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia. We propose a novel morphological grading system for both subtypes to compare lesion intensities and their possible clinical validity. Forty-two autopsy cases of MSA were separated into four grades (SND 0-III and OPCA 0-III) based on semiquantitative assessment of neuronal loss, astrogliosis, and presence of alpha-synuclein-positive glial cytoplasmic inclusions (GCI) in striatum, globus pallidus, substantia nigra, pontine basis, cerebellum, and inferior olives. Whereas a recent grading system restricted to SND reflected disease progression and dopa-responsiveness, there was considerable variation in the morphological combination between SND and OPCA, with only around half the cases with OPCA II (moderate) and III (severe) showing comparable grades of both types, whereas OPCA 0 and I (no or little degeneration) was combined with all grades of SND. Twenty-two cases showing OPCA 0 + SND II (n = 3), OPCA I + SND I-II (n = 11), and OPCA I + SND III (n = 8) were classified as pure or predominant SND, consistent with MSA-P. Twenty cases showing OPCA II + SND II/III (n = 7) and OPCA III + SND III (n = 13) were classified as predominant OPCA, consistent with MSA-C. In MSA-P, the mean age of onset was higher than it was in MSA-C (55.1 vs. 50.5 years), but the mean duration of illness was shorter in MSA-P (5.3 vs. 6.7 years). Presenting symptoms in MSA-P were mainly parkinsonism, whereas in MSA-C they were mainly gait disorders (14 vs. 1; P < 0.001). Among clinical key symptoms, parkinsonism was more frequent than were cerebellar signs in MSA-P; in MSA-C it was the reverse (P < 0.01), whereas other symptoms (autonomic/urinary failure) showed no differences. Parkinsonism was infrequent in MSA-C even when OPCA was associated with SND, suggesting a masking effect by cerebellar system involvement. High terminal Hoehn and Yahr stages were more frequent in MSA-P (P < 0.01), some with good-to-moderate initial levodopa (L-dopa) response. Although the proposed morphological grading of both MSA-P and -C correlates well with initial symptoms and clinical key features of both types, further prospective studies are required to validate the clinical utility of the proposed MSA grading scales for future intervention studies. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092088     DOI: 10.1002/mds.20537

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  54 in total

1.  Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C).

Authors:  Esteban Muñoz; Alex Iranzo; Sebastian Rauek; Francisco Lomeña; Judith Gallego; Doménec Ros; Joan Santamaría; Eduardo Tolosa
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 4.849

2.  Brain glucose metabolism in neuropathologically confirmed multiple system atrophy.

Authors:  Valtteri Kaasinen; Maria Gardberg; Marko Seppänen; Matias Röyttä; Riitta Parkkola; Jörgen Bergman
Journal:  J Neurol       Date:  2013-05-30       Impact factor: 4.849

Review 3.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

Review 4.  Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Authors:  Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning
Journal:  Mov Disord       Date:  2014-04-18       Impact factor: 10.338

Review 5.  Spreading of pathology in neurodegenerative diseases: a focus on human studies.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2015-01-15       Impact factor: 34.870

Review 6.  Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.

Authors:  Chao Peng; Ronald J Gathagan; Virginia M-Y Lee
Journal:  Neurobiol Dis       Date:  2017-07-24       Impact factor: 5.996

7.  Different loss of dopamine transporter according to subtype of multiple system atrophy.

Authors:  Hae Won Kim; Jae Seung Kim; Minyoung Oh; Jungsu S Oh; Sang Joo Lee; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-19       Impact factor: 9.236

8.  p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy.

Authors:  Yun Ju C Song; Ditte M S Lundvig; Yue Huang; Wei Ping Gai; Peter C Blumbergs; Peter Højrup; Daniel Otzen; Glenda M Halliday; Poul H Jensen
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

9.  Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy.

Authors:  Aimee W Kao; Caroline A Racine; Lovingly C Quitania; Joel H Kramer; Chadwick W Christine; Bruce L Miller
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

Review 10.  Multiple system atrophy: pathogenic mechanisms and biomarkers.

Authors:  Kurt A Jellinger; Gregor K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2016-04-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.